Population structure of Japanese extraintestinal pathogenic<i>Escherichia coli</i>and its relationship with antimicrobial resistance

Matsumura, Yasufumi; Noguchi, Taro; Tanaka, Michio; Kanahashi, Toru; Yamamoto, Masaki; Nagao, Miki; Takakura, Shunji; Ichiyama, Satoshi; Brg, th Jaid

doi:10.1093/jac/dkw530

Cited by 23 publications

(26 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the clade C isolates, the H30Rx status defined by the ybbW SNP-based PCR assay corresponded to subclade C2, except for 1 subclade C2 isolate in the ExPEC collection (BRG145, as mentioned above). These 86 C2 isolates were associated with bla CTX-M-15 (94.2%; whose presence was defined in previous studies [15,16]), confirming their relationship (4). The 202 C1-M27 and 180 C1-nM27 subclade isolates were associated with bla CTX-M-27 (98.0%) and bla CTX-M-14 (61.1%), as expected from our previous studies (8,15,16).…”

Section: Resultssupporting

confidence: 76%

“…These 86 C2 isolates were associated with bla CTX-M-15 (94.2%; whose presence was defined in previous studies [15,16]), confirming their relationship (4). The 202 C1-M27 and 180 C1-nM27 subclade isolates were associated with bla CTX-M-27 (98.0%) and bla CTX-M-14 (61.1%), as expected from our previous studies (8,15,16). The other 15 clade C isolates other than C1 or C2 were considered to belong to subclade C0 according to the current understanding of the clade C lineages (4-6).…”

Section: Resultssupporting

confidence: 76%

“…The ESBL collections comprised 460 ESBL-producing ST131 isolates that were collected in 10 acute-care hospitals in the Kyoto and Shiga prefectures in Japan from 2001 to 2012 (15). The ExPEC collection comprised 329 isolates that were collected in ten acute-care hospitals in five prefectures in Japan during December 2014 (all clinical isolates during the collection period) and included seven major ST complexes containing ST131 (32%), ST95 (13%), ST73 (8%), ST357/1876 (5%), ST69 (4%), ST38 (3%), and ST1193 (2%) (16). These isolates from the two collections were previously defined for ciprofloxacin susceptibility, the presence of ESBL genes, ST131 status using PCR detection of specific SNPs in mdh and gyrB (12) or fumC-fimH typing (17), O typing (rfb alleles) (18,19), fimH alleles using sequencing or H30-specific PCR (10), and H30Rx status using PCR detection of ybbW SNP (9).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Rapid Identification of Different Escherichia coli Sequence Type 131 Clades

Matsumura

Pitout

Peirano

et al. 2017

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

Escherichia coli sequence type 131 (ST131) is a pandemic clonal lineage that is responsible for the global increase in fluoroquinolone resistance and extendedspectrum-␤-lactamase (ESBL) producers. The members of ST131 clade C, especially subclades C2 and C1-M27, are associated with ESBLs. We developed a multiplex conventional PCR assay with the ability to detect all ST131 clades (A, B, and C), as well as C subclades (C1-M27, C1-nM27 [C1-non-M27], and C2). To validate the assay, we used 80 ST131 global isolates that had been fully sequenced. We then used the assay to define the prevalence of each clade in two Japanese collections consisting of 460 ESBL-producing E. coli ST131 (2001-12) and 329 E. coli isolates from extraintestinal sites (ExPEC) (2014). The assay correctly identified the different clades in all 80 global isolates: clades A (n ϭ 12), B (n ϭ 12), and C, including subclades C1-M27 (n ϭ 16), C1-nM27 (n ϭ 20), C2 (n ϭ 17), and other C (n ϭ 3). The assay also detected all 565 ST131 isolates in both collections without any false positives. Isolates from clades A (n ϭ 54), B (n ϭ 23), and C (n ϭ 483) corresponded to the O serotypes and the fimH types of O16-H41, O25b-H22, and O25b-H30, respectively. Of the 483 clade C isolates, C1-M27 was the most common subclade (36%), followed by C1-nM27 (32%) and C2 (15%). The C1-M27 subclade with bla CTX-M-27 became especially prominent after 2009. Our novel multiplex PCR assay revealed the predominance of the C1-M27 subclade in recent Japanese ESBL-producing E. coli isolates and is a promising tool for epidemiological studies of ST131.

show abstract

Section: Resultssupporting

confidence: 76%

Section: Resultssupporting

confidence: 76%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Rapid Identification of Different Escherichia coli Sequence Type 131 Clades

Matsumura

Pitout

Peirano

et al. 2017

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

show abstract

“…We investigated a total of 329 clinical E. coli isolates that were consecutively collected by a Japanese multicenter surveillance program (14). Of these isolates, 95 isolates (29%) were nonsusceptible (intermediate, 60 isolates; resistant, 35 isolates) to SAM, and 61 isolates (19%) were nonsusceptible to AMC.…”

Section: Resultsmentioning

confidence: 99%

Role of TEM-1 β-Lactamase in the Predominance of Ampicillin-Sulbactam-Nonsusceptible Escherichia coli in Japan

Noguchi

Matsumura

Kanahashi

et al. 2019

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

We investigated the epidemiology and resistance mechanisms of ampicillin-sulbactam-nonsusceptible Escherichia coli, focusing on the role of the TEM-1 β-lactamase. We collected all nonduplicate E. coli clinical isolates at 10 Japanese hospitals during December 2014 and examined their antimicrobial susceptibility, β-lactamases, TEM-1 transferability, TEM-1 β-lactamase activity, outer membrane protein profile, membrane permeability, and clonal genotypes. Among the 329 isolates collected, 95 were ampicillin-sulbactam nonsusceptible. Of these ampicillin-sulbactam-nonsusceptible isolates, β-lactamases conferring resistance to sulbactam, such as AmpC, were present in 33%. Hyperproduction of sulbactam-susceptible β-lactamases, TEMs with a strong promoter, were rare (5%). The remaining 59 isolates (62%) had only sulbactam-susceptible β-lactamases, including TEM-1 with a wild-type promoter (n = 28), CTX-Ms (n = 13), or both (n = 17). All 45 transconjugants from 96 donors with TEM-1 had higher ampicillin-sulbactam MICs (4 to 96 mg/liter) than the recipient (2 mg/liter). In donors with only TEM-1, TEM-1 activity correlated with the 50% inhibitory concentration of sulbactam and ampicillin-sulbactam MICs. The decreased membrane permeation of sulbactam was associated with an increased ampicillin-sulbactam MIC. The reduced permeation was partly attributable to deficient outer membrane proteins, which were observed in 57% of the ampicillin-sulbactam-nonsusceptible isolates with only TEM-1 and a wild-type promoter. Sequence type 131 (ST131) was the most common clonal type (52%). TEM-1 with a wild-type promoter primarily contributed to ampicillin-sulbactam nonsusceptibility in E. coli, with the partial support of other mechanisms, such as reduced permeation. Conjugative TEM-1 and the clonal spread of ST131 may contribute to the prevalence of Japanese ampicillin-sulbactam-nonsusceptible isolates.

show abstract

“…2 , 12 Data from Japanese Nosocomial Infections Surveillance suggest that E.coli causing bacteremia is increasing in the Japanese population. 14 Since antibiotic resistant ExPEC strains are also prevalent in the Japanese population, 15 the Phase 1 study described herein was conducted to investigate the safety, tolerability and immunogenicity of 3 different dose levels of ExPEC4V vaccine in healthy adult Japanese participants. This study was conducted in a dose-ascending manner as there was no prior clinical experience in the Japanese population.…”

Section: Introductionmentioning

confidence: 99%

Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: A phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants

Inoue

Ogawa²,

Tamura³

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

This Phase 1, randomized, double-blind, placebo-controlled study was conducted to evaluate the safety, tolerability and immunogenicity of different doses of ExPEC4V conjugate vaccine (4-16µg Polysaccharide [PS]/serotype) in healthy Japanese participants, stratified into younger (≥20 to <50 years) or older age groups (≥50 years). Within each age group, participants were randomized to a single vaccination with 1 of 3 dose levels of ExPEC4V (4, 8 and 16 µg PS/serotype) or placebo. Safety and tolerability were the primary objectives; immunogenicity was secondary. Of the 48 participants, 47 (98%) completed; one (2%) in the placebo group discontinued. A total of 48% participants had ≥1 AE (younger group: n = 13 [54%]; older group: n = 10 [41.7%]). Solicited and unsolicited AEs were reported in 44% and 8% participants, respectively in the combined ExPEC4V groups. Pain/tenderness (n = 11 [31%]) and redness (n = 9 [25%]) were the most frequently reported solicited local AEs, whereas fatigue (n = 4 [11%]), headache (n = 4 [11%]), muscle pain (n = 2 [6%]), and malaise (n = 5 [14%]) were the most common solicited systemic AEs in the combined ExPEC4V group. No serious AEs, deaths, or discontinuation due to AEs were reported. All doses were immunogenic with an increase in IgG (ELISA) geometric mean titers of at least 5-fold from baseline to Days 15 and 30 for all serotypes. Of participants vaccinated with ExPEC4V, 75% - 100% demonstrated an ELISA titer increase of ≥2-fold. Strong correlation observed between ELISA and OPK. ExPEC4V was well tolerated and elicited an immunogenic response at all dose levels (up to 16 µg PS/serotype) in healthy Japanese participants.

show abstract

Population structure of Japanese extraintestinal pathogenicEscherichia coliand its relationship with antimicrobial resistance

Cited by 23 publications

References 48 publications

Rapid Identification of Different Escherichia coli Sequence Type 131 Clades

Rapid Identification of Different Escherichia coli Sequence Type 131 Clades

Role of TEM-1 β-Lactamase in the Predominance of Ampicillin-Sulbactam-Nonsusceptible Escherichia coli in Japan

Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: A phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants

Contact Info

Product

Resources

About